Table. 1—

Patient demographics and baseline characteristics

CarbocysteinePlacebo
Subjects353354
Males273 (77)282 (80)
Age yrs65±965±9
Duration of COPD yrs9±910±9
Baseline spirometry
 FEV1 L1.07±0.411.12±0.43
 FEV1 % pred44±1545±15
 FVC L2.20±0.742.28±0.75
 FEV1/FVC %50±1350±13
GOLD stages
 II167 (47)177 (50)
 III139 (39)140 (40)
 IV47 (13)37 (11)
SGRQ total score42±1943±19
Medications for COPD prior to study
 β2-agonist76 (22)61 (17)
 Anticholinergic agents40 (11)36 (10)
 Inhaled corticosteroids64 (18)54 (15)
 Xanthines113 (30)95 (27)
  • Data are presented as n, n (%) or mean±sd. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; SGRQ: St George's Respiratory Questionnaire. Reproduced from [54] with permission from the publisher.